Biotech Startups

Ankyra Therapeutics is a biopharmaceutical company developing drugs, with a team that has collectively contributed to bringing seven drugs to global market approval.

1 investor

Anocis is a pharmaceutical drug discovery company focused on early-stage development in neuroscience, particularly ion channel research. The company serves pharmaceutical and biotech clients seeking collaborative drug discovery services and technologies.

1 investor

Anomaly develops functional ingredients through advanced fermentation, engineering microbes to convert simple sugars into ingredients for nutrition, crop protection, and personal care. It aims to replace extraction-based ingredient supply chains with on-demand biomanufacturing.

1 investor

ANRis develops nucleic acid therapeutics using proprietary SNPD-siRNA technology for drug discovery and treatment delivery in medical and pharmaceutical applications.

1 investor

Ansella Therapeutics develops novel vaginal formulations for women's health conditions using biomimetic materials science and biomedical engineering, focused on treating menopause, vaginal dryness, dyspareunia, vaginal mucositis, endometriosis, uterine fibroids, and vaginal infections.

1 investor

Anser Bio is a biotech company focused on cancer research and drug development, working on areas such as exosome-based therapeutics, protein purification, and cell technologies. The team combines expertise in immuno-oncology, cell therapy, and translational R&D.

1 investor

Antabio is a clinical-stage biopharmaceutical company developing novel antibacterial treatments for drug-resistant, Gram-negative bacterial infections identified as critical priorities by the WHO and CDC, with a focus on life-threatening hospital-acquired infections. Its lead program, Meropenem-Pilabactam, is a β-lactam/β-lactamase inhibitor combination for treating multidrug-resistant infections in hospital wards and ICUs.

1 investor

Antaros Medical is a development partner to the pharmaceutical industry that uses medical imaging to provide evidence-based decision support during clinical drug development. It combines imaging technology with expertise in drug development and disease mechanisms.

1 investor

Antelope Surgical Solutions develops multimodal small-molecule radioligand agents that bind to cancer cells for diagnostic, radiotherapeutic, and fluorescence-guided surgical use, making tumor margins visible to surgeons during operations. The company operates a GMP manufacturing facility with robotic high-throughput synthesis and has received its first FDA IND clearance for its lead agent.

1 investor

Anthriq develops the Human Body API, a hardware and software platform that reads and writes human biosignals and psychophysiological data to enable developers to build brain-computer interface and human-computer interaction products. The company provides a full-stack foundation for innovators working on neurotech and biotech applications.

1 investor

Antidote connects patients with relevant clinical trials and helps trial sponsors recruit participants through precision matching, aiming to reduce delays in medical research. It operates in the clinical trial recruitment space, serving both patients seeking trials and research sponsors filling studies.

1 investor

Rezolute develops ersodetug, an intravenously administered monoclonal antibody targeting the insulin receptor to treat hypoglycemia caused by hyperinsulinism, with late-stage clinical programs in congenital hyperinsulinism and tumor-related hyperinsulinism.

1 investor

Anumana is an AI-driven health technology company developing software-as-a-medical-device (SaMD) solutions that apply AI to standard 12-lead ECG data to detect early signs of cardiovascular disease and support clinical decision-making. Its portfolio includes FDA-cleared ECG-AI algorithms, generative imaging applications, and real-time procedural support tools for use across diagnostic and intraprocedural cardiac care.

1 investor

Anyo Labs develops AI-enabled computational chemistry technology for drug discovery, building on research from the University of Gothenburg. The company serves pharmaceutical and biotech organizations seeking to accelerate the drug development process.

1 investor

AOBiome Therapeutics is a late-stage biotechnology company developing microbiome-based treatments for inflammatory skin conditions such as atopic dermatitis and pruritus. Its lead candidate, B244, uses a single strain of Ammonia Oxidizing Bacteria to moderate immune response by simultaneously down-regulating multiple inflammatory markers (IL-4, IL-5, IL-13, IL-31).

1 investor

Applied BioCode develops multiplex diagnostic testing products for infectious disease detection using proprietary barcoded magnetic bead technology. The company serves clinical and research markets with panels that detect bacterial and fungal pathogens and antimicrobial resistance markers.

1 investor

Apeiron Therapeutics is a biotech company developing small-molecule therapeutics with a focus on immuno-oncology and oncology drug discovery. The company operates across the Chinese and global healthcare markets, spanning target identification, medicinal chemistry, and clinical development.

1 investor

Apex Labs is a biotechnology and emerging therapeutics company developing clinical solutions, likely focused on psychedelic-assisted therapies and drug development. The company is led by a team with deep expertise in pharmaceutical development, clinical trials, commercialization, and regulatory affairs.

1 investor

1 investor

Aplantex operates a modular green biotechnology platform that uses proprietary photosynthetic "phytoreplicators" to locally produce plant biomass and extract active plant compounds such as polyphenols with antioxidant, anti-inflammatory, antimicrobial and anti-aging properties. It supplies certified molecules to the food, pharmaceutical, cosmetics, and natural health industries.

1 investor

1 investor

ApoGlyx develops small-molecule aquaporin-9 inhibitors to treat severe inflammatory and metabolic diseases, including acute pancreatitis and diabetes. The company progresses its lead candidate RG210179 through clinical development and collaborates with academic institutions on drug discovery and validation.

1 investor

Applause Pharma develops therapeutic drugs using rare earth elements as a common platform, leveraging proprietary technologies in reactive oxygen species scavenging, enzyme inhibition, and ion reactions to address unmet medical needs. The company focuses on biotech innovation with scientific evidence-based approaches to treat various diseases.

1 investor

Applied Quantum Materials designs and manufactures silicon, carbon, and germanium nanomaterials and their chemical precursors for advanced technology applications. The company customizes nanomaterial properties for use in batteries, displays, sensing, photovoltaics, and biological imaging.

1 investor